Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04753996 · ClinicalTrials.gov registry record
Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
A clinical trial of Cholangiocarcinoma and Primary Sclerosing Cholangitis, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT04753996 is a study of Cholangiocarcinoma and Primary Sclerosing Cholangitis that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 300 participants, below the 381-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (21% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04753996, a study of Cholangiocarcinoma and Primary Sclerosing Cholangitis, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to create a collection of bile, bile duct brushings and medical information from people with Primary Sclerosing Cholangitis (PSC) and controls to learn more about changes that occur in the liver.
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2021-03-08 |
| Est. Completion | 2035-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04753996
The ClinicalTrials.gov registry entry for NCT04753996 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 381-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (21% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT04753996 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04753996 about?
NCT04753996 is a clinical study titled "Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients". The purpose of this research is to create a collection of bile, bile duct brushings and medical information from people with Primary Sclerosing Cholangitis (PSC) and controls to learn more about changes that occur in the liver.
What is the current status of trial NCT04753996?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2021-03-08. Estimated completion is 2035-01-01.
What conditions does trial NCT04753996 study?
This clinical trial studies the following conditions: Cholangiocarcinoma, Primary Sclerosing Cholangitis, PSC.
Who is sponsoring clinical trial NCT04753996?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04753996 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
RECRUITING · Phase 2
-
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
RECRUITING
-
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RECRUITING · Phase 4
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
RECRUITING · Phase 2
-
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.